Axoft’s novel Fleuron material is up to 10,000x softer than the polyimide used in existing brain implants. It offers superior biocompatibility, reduces tissue scarring and lead migration, and improves high-resolution neural data stability over time.
Axoft, a neurotechnology company, announced it has raised an oversubscribed $55 million Series A led by C.P. Group Innovation. Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment and Gaorong Ventures also participated in the round.
With more than $60 million in total funding raised, Axoft will use the capital to expand its current clinical trials globally and progress U.S.
regulatory approval of its implantable Brain-Computer Interfaces(iBCIs), which have already demonstrated the ability to safely decode brain signals, and offer a path for improving the standard of care for prognosis and communication in disorders of consciousness.
Axoft will also use the capital to build a good manufacturing practice(GMP) facility to mass produce its iBCIs.
Neurological disorders are the leading cause of ill health and disability worldwide, affecting 1 in 3 people. iBCIs have the potential to transform how these conditions are assessed and treated by providing direct, high resolution access to neural activity that cannot be captured through traditional exams or external imaging alone.
Such neural data can enable the use of AI-driven tools for the discovery of novel disease biomarkers, support more personalized treatments and power a new generation of AI models for brain health.
Beyond clinical utility, high quality neural data is itself an increasingly important frontier.
Large-scale, stable recordings from the human brain can deepen our understanding of biological intelligence, and provide direct training data for the design and training of future AI systems. However, these opportunities have been limited by the shortcomings of conventional neural implants.
Existing iBCIs are typically built from rigid materials, which can cause tissue scarring and implant movement over time, which in turn negatively impacts the quality and volume of data that can be collected.
Axoft builds stable, high-density iBCIs to leverage the naturally scalable language of the brain.
The company’s iBCIs are made using its proprietary Fleuron material, which enables high quality neural data capture over longer periods of time due to the material’s superior biocompatibility.
Fleuron is up to 10,000x softer than the polyimide used in existing iBCIs, and delivers 8x more region access, 32x more sensor/stimulators per thread than standard flexible probes and over 60% less signal attenuation than polyimide.
Notably, the material can be used for a wide range of applications with hardware-biology interfaces, including biohybrid devices, organ-on-a-chip, microfluidics and neural interfaces.
“At Axoft, the neural data quality we unlock doesn't just make iBCIs more effective, it opens the door to minimally invasive surgery, allows access to deeper brain regions and enables the next generation of AI-driven real-time decoding. Better neural signals are the foundation everything else is built on,” said Dr. Paul Le Floch, co-founder and CEO of Axoft.
taewoo.choi
댓글
0